ONWARD Medical Launches ADR Program to Boost US Presence

ONWARD Medical, renowned for its pioneering work in Spinal Cord Injury (SCI) therapies, has launched a Level 1 American Depositary Receipt (ADR) program partnered with BNY, facilitating US trading. This strategic expansion to the OTCQX Best Market is set to broaden ONWARD’s investor base, following recent FDA clearances and the commercial launch of their ARC Therapy systems. 

Headquartered in Eindhoven, ONWARD Medical is a key player in the medical technology field, dedicated to advancing therapeutic solutions for movement disabilities. The company’s new ADR program simplifies access for US investors, aligning with the trend where funds are keen on US dollar transactions. BNY Mellon, acting as the depositary bank, underscores the ADR issuance, marking an important venture for ONWARD into the US financial market. With this move, ONWARD aims to attract a wider audience, potentially increasing stock liquidity and expanding their capital footprint. Recognition of their breakthrough device designations from the FDA furthers ONWARD’s standing in the industry, providing a strong foundation for this US engagement.